Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 1998

View Archived Issues

C-C chemokines implicated in the pathogenesis of CHF

Company Profile: Gemma Biotechnology

Novo Nordisk: Annual Report 1997

New antitumor compounds from Ajinomoto

Sanguine funds development of blood substitute

Noven and Novartis establish joint venture to promote Vivelle

FDA approves SuperGen's injectable mitomycin

GenVec, Fuso collaborate on cancer gene therapies

Profile of a factor Xa inhibitor in development at Yamanouchi

Patient enrollment complete for phase III trial of GL-701 in SLE

Hemolink cleared by FDA for phase II testing in chronic anemia

Signal awarded SBIR phase II grant for osteoporosis research

SSRIs safe and effective for elderly depressed patients with heart disease

Naked DNA vaccine shows promise against malaria

Bisaramil compared to lidocaine for effects on Na+ channels

Results of Neutralase phase II trial presented

Sagami presents new anti-H. pylori agents

Apoptosis-inducing iminodiacetic acid derivatives described by Mitsui Toatsu

BE-56980: new antitumor agent discovered by Banyu

Research at Kyorin leads to effective blood glucose-lowering agents

Pharmacological profile of Otsuka's OPB-2045

WF-10 to enter U.S. trials for follicular lymphoma

Spotlight on P2Y2 agonists: a new target for cystic fibrosis

FDA advisory committee recommends approval of drug combination for hepatitis C

Results from clinical trial of Altropane for the diagnosis of PD

Fuisz and Pfizer enter drug delivery collaboration

SB-240563, an anti-IL-5 MAb for the treatment of asthma

Scios submits NDA for Natrecor

CytoMed's 5-LO inhibitor shows potential in asthma; clinical trials imminent

Advisory committee recommends FDA approval for TB treatment

FDA approves test to identify risk of preterm labor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...